Evidence map›Paper›PMID 24370448›Full record

ArticleNutrition, metabolism, and cardiovascular diseases : NMCD2014

Fatty acids and TxA(2) generation, in the absence of platelet-COX-1 activity.

A P DeFilippis, S N Rai, A Cambon, R J Miles, A S Jaffe, A B Moser, R O Jones, R Bolli, S P Schulman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nutrition, metabolism, and cardiovascular diseases : NMCD, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

A P DeFilippisUniversity of Louisville, Rudd Heart & Lung Center/Kentucky One Health, Louisville, KY, USA; The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA. Electronic address: apdefi01@louisville.edu.
S N RaiBiostatistics Shared Facility, JG Brown Cancer Center, University of Louisville, Louisville, KY, USA.
A CambonDepartment of Bioinformatics and Biostatistics, University of Louisville, Louisville, KY, USA.
R J MilesUniversity of Louisville School of Medicine, Louisville, KY, USA.
A S JaffeCardiovascular division, Mayo Clinic, Rochester, MN, USA.
A B MoserThe Hugo W. Moser Research Institute, The Kennedy Krieger Institute, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
R O JonesThe Hugo W. Moser Research Institute, The Kennedy Krieger Institute, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
R BolliDivision of Cardiovascular Medicine, University of Louisville, Louisville, KY, USA.
S P SchulmanJohns Hopkins University School of Medicine, Baltimore, MD, USA.
University of Louisville · USJohns Hopkins University · USKennedy Krieger Institute · USMayo Clinic in Arizona · US

Funding

Tumor Necrosis Factor Modulation of CPCsP01HL078825 · NHLBI · UNIVERSITY OF LOUISVILLE · PI BOLLI, ROBERTO · 2005 to 2021
$37.6M
NHLBI NIH HHS P01 HL078825
6 · The paper itself

Abstract

BACKGROUND AND

aimsOmega-3 fatty acids suppress Thromboxane A(2) (TxA(2)) generation via mechanisms independent to that of aspirin therapy. We sought to evaluate whether baseline omega-3 fatty acid levels influence arachidonic acid proven platelet-cyclooxygenase-1 (COX-1) independent TxA(2) generation (TxA(2) generation despite adequate aspirin use). METHODS AND

resultsSubjects with acute myocardial infarction, stable CVD or at high risk for CVD, on adequate aspirin therapy were included in this study. Adequate aspirin action was defined as complete inhibition of platelet-COX-1 activity as assessed by <10% change in light transmission aggregometry to ≥1 mmol/L arachidonic acid. TxA(2) production was measured via liquid chromatography-tandem mass spectrometry for the stable TxA(2) metabolite 11-dehydro-thromboxane B2 (UTxB2) in urine. The relationship between baseline fatty acids, demographics and UTxB(2) were evaluated. Baseline omega-3 fatty acid levels were not associated with UTxB(2) concentration. However, smoking was associated with UTxB(2) in this study.

conclusionBaseline omega-3 fatty acid levels do not influence TxA(2) generation in patients with or at high risk for CVD receiving adequate aspirin therapy. The association of smoking and TxA(2) generation, in the absence of platelet COX-1 activity, among aspirin treated patients warrants further study.

Indexed as

AgedAspirinBiomarkersBlood PlateletsCardiovascular DiseasesChromatography, LiquidCyclooxygenase 1Cyclooxygenase InhibitorsFatty Acids, Omega-3FemaleHumansMaleMiddle AgedPlatelet AggregationPlatelet Function TestsSmoking11-dehydro-thromboxane B2AspirinBiomarkersCyclooxygenase 1Cyclooxygenase InhibitorsFatty Acids, Omega-3PTGS1 protein, humanThromboxane A2Thromboxane B2Aspirin resistanceOmega-3 fatty acidsPlatelet activationSmokingThromboxane

Identifiers

PMID24370448
PMCPMC4409424
OpenAlexW2133328105

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.